

Accuracy.
It's in our DNA.

Introducing FoundationACT™ - the best-in-class, reliable blood-based circulating tumor DNA assay that provides new options for patients when tissue biopsy is not feasible.

Transforming Cancer Care

At Foundation Medicine, we are leading a transformation in cancer care, where each patient's treatment is informed by a deep understanding of the molecular changes driving their disease.

BEST-IN-CLASS GENOMIC PROFILES AND ACCESS SOLUTIONS

We offer a suite of best-in-class comprehensive genomic profiles and access solutions to help you care for every cancer patient.

CLINICAL PROFILES

FoundationOne® - Gold standard for tissue-based testing

FoundationOne Heme® - Best-in-class comprehensive genomic profile for hematological malignancies and sarcomas

FoundationACT™ - Best-in-class liquid biopsy for solid tumors

DECISION SUPPORT TOOLS

FoundationICE® - An online portal for your test results and test ordering

SUPPORT SERVICES

FoundationACCESS™ - Solutions to support access to testing, therapies and trials



68,000+ Patients profiled to date*



25+ Pharma partners rely on our genomic profiles to help shape their drug development strategies*



Chosen platforms for **300+** clinical trials*


A Trusted Liquid Biopsy Solution

Introducing FoundationACT (Assay for Circulating Tumor DNA), a precise blood-based genomic profiling assay powered by Foundation Medicine.

When a tissue biopsy is not feasible, our liquid biopsy solution, FoundationACT, delivers reliable answers to uncover new treatment options for patients.

- ✓ **Unparalleled accuracy** with 99% sensitivity and 99% specificity (PPV)¹
- ✓ **Analytically and clinically validated for all four types of alterations** - Base substitutions, Insertions and deletions, Copy number variations and Rearrangements
- ✓ **Connectivity with FoundationOne, Gold Standard for Tissue-Based Testing** - Compare FoundationACT results with previous FoundationOne or FoundationACT testing results. FoundationACT is the only platform that allows you to get an integrated view of your patient's tumor genomics by connecting blood with tissue results

Detecting accurate results from liquid biopsy is a significant challenge due to the relative proportion of tumor content in blood. FoundationACT was created to address these challenges and, as a result, achieves the superior performance you can expect from Foundation Medicine.



Tumor content in blood can be as low as 1%.

1. FoundationACT Analytical Validation, data on file. Validation to be submitted for publication in 2016.

Optimized at Every Step to Deliver Unparalleled Accuracy



ORDER

A physician orders the FoundationACT assay and sends two tubes of blood using the FoundationACT kit



GENOMIC PROFILING

Every step is optimized to generate accurate results. Enhanced sample preparation methodology captures a high quantity of cell-free DNA. Proprietary FragTag™ technology and state-of-the-art algorithms support highly accurate variant calling



REPORTING

Receive results within 14 days. Connectivity with tissue-based testing that provides an integrated view of a patient's tumor genomics by comparing results with previous blood or tissue testing

...Because Every Answer Matters

The FoundationACT Patient Profile

FoundationACT was developed for patients who are not candidates for comprehensive genomic profiling with FoundationOne due to lack of tissue. The following factors may preclude patients from obtaining FoundationOne testing:

- ✓ Insufficient or inadequate tissue from a recent biopsy
- ✓ Biopsy poses an unacceptable risk to the patient as assessed by treating physician
- ✓ Progression on targeted therapy is suspected and repeat biopsy is infeasible

The science behind which tumors shed ctDNA and during what stages of cancer still remains unclear. Foundation Medicine is conducting a well-designed clinical study of 2,000 patients to ascertain in which diseases a highly validated ctDNA assay is an appropriate substitute for tissue-based analysis.

More Than Just a Test

We partner with you at every step of the process

We deliver an end-to-end solution from testing to obtaining access to targeted therapies, enabling you to deliver the best possible care for your patients.



FoundationACCESS Reimbursement and Financial assistance - To ensure financial considerations are never a barrier to obtaining Foundation Medicine testing



FoundationACCESS Careline - Provides comprehensive case management services to help uninsured, underinsured and insured patients who are facing obstacles obtaining prescribed targeted therapies and increases physicians' ability to act on FoundationACT results



FoundationACCESS Trial Navigator - Helps match patients to clinical trials and assists with the enrollment process based on FoundationACT test results



FoundationICE - Online decision support tool that allows physicians to order new tests and manage test results for their patients



PatientMatch™ is a brand new approach to increase the actionability of comprehensive genomic profiling results. With PatientMatch, physicians can connect with other physicians and share experiences treating patients with similar genomic profiles to inform your treatment decisions



Contact Your Local Sales Representative
To Order FoundationACT For Your Patients

At Foundation Medicine, we are committed to providing excellent customer service. If you have any questions, please connect with us at:

Call 888.988.3639 Fax 617.418.2290
Email client.services@foundationmedicine.com

Learn more at www.foundationone.com

© 2016 Foundation Medicine, Inc. Foundation Medicine®, FoundationOne® and FoundationICE® are registered trademarks. FoundationACT™, FoundationACCESS™ and FragTag™ are trademarks of Foundation Medicine, Inc.

ACT-S-002-20160126